Table 2. Molecular subtype conversion of breast cancer in patient-matched pair samples (n = 17).
| Pair No. | PAM50 |
IHC |
||
|---|---|---|---|---|
| Breast | Brain | Breast | Brain | |
| 1 | LumA | LumB | ER+ | TN |
| 2 | LumA | LumA | ER+ | ER+ |
| 3 | Basal | Basal | TN | TN |
| 4 | Her2 | LumA | HER2+ | HER2+ |
| 5 | LumA | Her2 | ER+ | ER+ |
| 6 | Her2 | Her2 | TN | TN |
| 7 | LumA | Her2 | ER+ | TN |
| 8 | Basal | Basal | TN | TN |
| 9 | Her2 | Her2 | HER2+ | HER2+ |
| 10 | Basal | Basal | TN | TN |
| 11 | LumA | LumB | ER+ | ER+ |
| 12 | Her2 | Normal | HER2+ | HER2+ |
| 13 | Basal | Basal | TN | TN |
| 14 | Basal | Basal | TN | TN |
| 15 | LumA | Her2 | HER2+ | HER2+ |
| 16 | Basal | Basal | TN | TN |
| 18 | Normal | Basal | TN | TN |
IHC, immunohistochemistry, Lum, luminal; ER, estrogen receptor; TN, triple negative.